UNSPSC 51151657: Oxybutynin

This classification denotes an antimuscarinic agent with the molecular formula C22H31NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K9P6MC7092, chemically known as cyclohexaneglycolic acid, alpha-phenyl-, 4-(diethylamino)-2-butynyl ester but generally known as oxybutynin, which bears US NIH Compound Identifier 4634. European Medicines Agency schedules Oxybutynin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09558MIG.

UNSPSC 51151657 Oxybutynin is a Commodity code that nominally covers a specific pharmaceutical product, but the recent state and local opportunities tagged under it show substantial divergence from this narrow classification. Seminole County, Florida and the Texas Health and Human Services Commission have posted solicitations under this code for much broader pharmaceutical procurement — naloxone and drug deactivation systems, and direct-to-manufacturer prescription fulfillment programs respectively. The actual work being bought under the code spans pharmaceutical sourcing, pharmacy benefit management restructuring, and community health supply chains rather than oxybutynin specifically. Issuing bodies include county health authorities and state health agencies, reflecting the code's use as a catch-all tag for pharmaceutical and pharmacy-related procurement when more precise classification codes are not applied or available.

Geographic activity centers on Florida and Texas based on recent postings. Seminole County's IFB 60459723LAS, posted June 30, 2026, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, Florida; the response deadline was July 26, 2023 (note the historical date discrepancy in source materials). The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would bypass traditional pharmacy benefit managers and wholesalers. The RFI functions as an exploratory procurement mechanism rather than a binding solicitation, designed to inform the state's future contracting approach before issuing a formal RFP. Neither opportunity specifies explicit set-aside designations, though both require standard federal compliance mechanisms such as E-Verify and drug-free workplace certification.